Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

Jun 2 2010

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that data on FOLOTYN^® (pralatrexate injection) will be presented at two upcoming medical conferences: the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4-8 in Chicago, Illinois, and at the 15^th Congress of the European Hematology Association (EHA), which will be held June 10-13 in Barcelona, Spain.

“Pralatrexate Efficacy and Tolerability in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)”

"At ASCO and EHA, further analyses of the final efficacy data from our PROPEL pivotal trial of FOLOTYN expand our understanding of the clinical benefit for patients with relapsed or refractory peripheral T-cell lymphoma," said Charles Morris, MB ChB, MRCP, chief medical officer at Allos Therapeutics. "In addition, at EHA, updated interim data from our Phase 1 trial of FOLOTYN in cutaneous T-cell lymphoma, a disease that is related to PTCL but follows a more indolent clinical course, show that FOLOTYN is active in this population. In addition we have an ASCO abstract describing an ongoing Phase 2 trial in B-cell lymphoma, part of our commitment to further exploring FOLOTYN's utility in a broad range of cancers."

FOLOTYN, a folate analogue metabolic inhibitor, is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Allos is also developing FOLOTYN in other potential indications.

Information regarding the ASCO presentations and abstracts is below. Full abstracts can be viewed on the ASCO website at www.asco.org and will be published in ASCO Annual Meeting Proceedings Part I.

Presentation Date/Time: Saturday, June 5, 8:00 a.m. - 12:00 p.m. (CDT)
Poster Title: "Pralatrexate in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL): Relationship Between Response and Survival"
First Author: Andrei R. Shustov, M.D., Seattle Cancer Care Alliance
Abstract Number: 8054
Location: S Hall A2 of the McCormick Convention Center, Chicago, Illinois

Abstract Title: "A Phase 2, Single-Arm, Open-Label Study of Pralatrexate in Patients with Aggressive Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL): Study PDX-015"
First Author: Julie E. Chang, M.D., University of Wisconsin Hospital and Clinics
Abstract Number: e18568
Location: Publication only

Information regarding the EHA presentations is below. Full abstracts can be viewed on the EHA website at http://eha.eurocongres.com.

Presentation Date/Time: Friday, June 11, 5:45 - 7:00 p.m.
Poster Title: "Pralatrexate Activity in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL): Relationship Between Response at Cycle 1 and Subsequent Survival"
First Author: Bertrand Coiffier, M.D., Ph.D., Hospices Civils de Lyon Pierre-Benite, France
Abstract Number: 1981
Location: Hall 6 of the Gran Via Conference Center, Barcelona, Spain

Presentation Date/Time: Friday, June 11, 5:45 - 7:00 p.m.
Poster Title: "Pralatrexate Efficacy and Tolerability in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)"
First Author: Steven Horwitz, M.D., Memorial Sloan-Kettering Cancer Center
Abstract Number: 2117
Location: Hall 6 of the Gran Via Conference Center, Barcelona, Spain